ATE299936T1 - Fas antigen-derivate - Google Patents

Fas antigen-derivate

Info

Publication number
ATE299936T1
ATE299936T1 AT97918354T AT97918354T ATE299936T1 AT E299936 T1 ATE299936 T1 AT E299936T1 AT 97918354 T AT97918354 T AT 97918354T AT 97918354 T AT97918354 T AT 97918354T AT E299936 T1 ATE299936 T1 AT E299936T1
Authority
AT
Austria
Prior art keywords
fas antigen
amino acid
derivative
antigen derivative
fas
Prior art date
Application number
AT97918354T
Other languages
English (en)
Inventor
Norio Mochida Nakamura
Shigekazu Nagata
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE299936T1 publication Critical patent/ATE299936T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97918354T 1996-05-02 1997-05-01 Fas antigen-derivate ATE299936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13576096 1996-05-02
PCT/JP1997/001502 WO1997042319A1 (en) 1996-05-02 1997-05-01 NOVEL Fas ANTIGEN DERIVATIVES

Publications (1)

Publication Number Publication Date
ATE299936T1 true ATE299936T1 (de) 2005-08-15

Family

ID=15159230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918354T ATE299936T1 (de) 1996-05-02 1997-05-01 Fas antigen-derivate

Country Status (7)

Country Link
US (2) US6306395B1 (de)
EP (1) EP0965637B1 (de)
AT (1) ATE299936T1 (de)
AU (1) AU2650597A (de)
CA (1) CA2253494A1 (de)
DE (1) DE69733773T2 (de)
WO (1) WO1997042319A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905684B1 (en) 1997-11-10 2005-06-14 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
EP1077069B1 (de) * 1998-05-14 2007-05-02 Mochida Pharmaceutical Co., Ltd. Prävention und therapie von leberzirrhosen
ATE333287T1 (de) 1998-05-29 2006-08-15 Mochida Pharm Co Ltd Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
ATE324444T1 (de) * 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1418935A1 (de) * 2001-08-01 2004-05-19 Genset S.A. Genobix agonisten und antagonisten zur verwendung bei der behandlung von stoffwechselkrankheiten
GB2381122B (en) * 2001-10-16 2006-04-05 Zetex Plc Termination structure for a semiconductor device
AU2003278833A1 (en) * 2002-09-19 2004-04-08 Cornell Research Foundation, Inc. Homing peptides to receptors of heart vasculature
DK1606318T3 (da) 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
DK2101877T3 (da) 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
US20090196868A1 (en) * 2007-09-06 2009-08-06 Apogenix Gmbh Methods and compositions for preventing radiation-induced pneumonitis
ES2608835T3 (es) * 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
CA2877989C (en) 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
EP2874659B1 (de) 2012-07-18 2016-07-13 Apogenix AG Inhibitoren des cd95-signalweges zur behandlung von mds
EP3076179A1 (de) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnose und behandlung von minderwertigen glioma
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0510691B1 (de) * 1991-04-26 2004-11-03 Osaka Bioscience Institute Für ein menschliches Zelloberflächen-Antigen kodierende DNS
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JPH07289266A (ja) 1994-04-21 1995-11-07 Mochida Pharmaceut Co Ltd ヒトＦａｓ抗原バリアント及びそれをコードする新規ＤＮＡ

Also Published As

Publication number Publication date
WO1997042319A1 (en) 1997-11-13
US6953847B2 (en) 2005-10-11
US20020044944A1 (en) 2002-04-18
US6306395B1 (en) 2001-10-23
AU2650597A (en) 1997-11-26
DE69733773T2 (de) 2006-04-20
CA2253494A1 (en) 1997-11-13
EP0965637B1 (de) 2005-07-20
EP0965637A4 (de) 2002-09-25
DE69733773D1 (de) 2005-08-25
EP0965637A1 (de) 1999-12-22

Similar Documents

Publication Publication Date Title
DE69733773D1 (de) Fas ANTIGEN-DERIVATE
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
DK0670898T3 (da) Interleukin-3 (IL-3)-mutantpolypeptider
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
KR960704934A (ko) 항혈전활성을 갖는 펩티드 및 이의 제조방법(Peptide having antithrombotic activity and process for producing the same)
MY127575A (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
DE69030937D1 (de) Mutanten von Interleukin-3
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
DE60313982D1 (de) Dimere von thrombinpeptidderivaten
AU6961601A (en) Transport peptides among which c-terminal E<sup>rns</sup> peptide and analogues thereof
WO2000058465A3 (en) Flint polypeptide analogs
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
ATE342978T1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
WO2003022867A3 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
DE69925817D1 (de) Rekombinante onconase und fusionsproteine davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties